BRINSUPRI™ (brensocatib) Becomes First FDA-Approved Treatment for Bronchiectasis
August 12, 2025 marks a new chapter in care for patients worldwide
Tuesday, August 12, 2025, is a monumental day for the bronchiectasis community. The U.S. Food and Drug Administration (FDA) has officially approved BRINSUPRI™ (brensocatib), the first treatment ever developed specifically for bronchiectasis in adults and pediatric patients aged 12 and older.
This landmark achievement is the result of years of dedication, innovation, and collaboration. We are deeply grateful for the innovation and leadership of Insmed, the tireless work of physicians and researchers, and—most importantly—the courage of the patients who participated in the clinical trials.
Why This Approval Matters
Bronchiectasis is a chronic lung condition that causes irreversible damage to the airways, leading to repeated lung infections, persistent cough, and reduced quality of life. For decades, patients have relied only on symptom management and antibiotics to treat flare-ups—there has been no approved therapy targeting the disease itself.
BRINSUPRI’s FDA approval represents the first time a therapy has been developed to slow the progression of bronchiectasis, not just treat its symptoms. This offers hope to the millions living with the condition, including those also managing nontuberculous mycobacterial (NTM) lung disease.
The Journey to Approval
The approval is the culmination of rigorous research, clinical trials, and the participation of patients who bravely volunteered to test new possibilities. Clinical data showed that Brensocatib can significantly reduce exacerbations (flare-ups), improve lung function, and enhance quality of life for patients.
“This is more than a medical milestone—it’s a turning point for a community that has waited far too long for treatment options,” said Amy Leitman, President of NTM Info & Research.
A Ripple Effect for Future Treatments
When one treatment succeeds, it opens the door for more innovation. We have seen how landmark approvals accelerate additional research and attract new investment into areas that have been underserved. Brensocatib’s success is a clear signal that momentum is building for bronchiectasis and NTM lung disease treatment development.
Walking the Path Together
In the past, bronchiectasis and NTM patients have often walked a lonely path, facing misunderstanding, stigma, and limited resources. Thanks to the trailblazing efforts of researchers, advocates, and industry leaders, we are now walking together toward a future filled with possibility.
At NTM Info & Research, it has been an honor to work alongside exceptional people—patients, caregivers, clinicians, and scientists—who have committed themselves to progress. This milestone belongs to all of us.
Learn More & Stay Informed
For more details, we encourage you to read the full announcements from Insmed:
We will continue to provide updates on how patients can access Brensocatib, what it means for long-term care, and how it may fit into treatment plans.
Today, we celebrate. Tomorrow, we will keep going—together.